AlloVir's RSV Therapy Is Underappreciated Gem, BofA Comments On Future Potential
Portfolio Pulse from Shivani Kumaresan
BofA Securities analyst Jason Zemansky initiated coverage on AlloVir Inc (NASDAQ:ALVR) with a Buy rating and a price target of $17. AlloVir is a clinical-stage biotech company advancing cell therapies for prevention/treatment of viruses in immunocompromised patients. The analyst sees a significant upside to the shares at current levels. ALVR shares are trading higher by 13.81% at $2.81 on the last check Friday.
August 18, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BofA Securities analyst Jason Zemansky initiated coverage on AlloVir Inc with a Buy rating and a price target of $17. The analyst sees a significant upside to the shares at current levels.
The analyst's positive outlook on AlloVir Inc, along with a Buy rating and a price target of $17, indicates a bullish sentiment towards the company. This could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100